PL1928438T3 - Zastosowanie ibudilastu do leczenia uzależnień od środków odurzających - Google Patents

Zastosowanie ibudilastu do leczenia uzależnień od środków odurzających

Info

Publication number
PL1928438T3
PL1928438T3 PL06815512T PL06815512T PL1928438T3 PL 1928438 T3 PL1928438 T3 PL 1928438T3 PL 06815512 T PL06815512 T PL 06815512T PL 06815512 T PL06815512 T PL 06815512T PL 1928438 T3 PL1928438 T3 PL 1928438T3
Authority
PL
Poland
Prior art keywords
ibudilast
treating drug
drug addictions
addictions
treating
Prior art date
Application number
PL06815512T
Other languages
English (en)
Inventor
Kirk W Johnson
Linda May Rothblum Watkins
Original Assignee
Avigen Inc
Univ Colorado Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avigen Inc, Univ Colorado Regents filed Critical Avigen Inc
Publication of PL1928438T3 publication Critical patent/PL1928438T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL06815512T 2005-09-26 2006-09-26 Zastosowanie ibudilastu do leczenia uzależnień od środków odurzających PL1928438T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US72056805P 2005-09-26 2005-09-26
US81003806P 2006-05-31 2006-05-31
EP06815512A EP1928438B1 (en) 2005-09-26 2006-09-26 Use of ibudilast for treating drug addictions
PCT/US2006/037563 WO2007038551A2 (en) 2005-09-26 2006-09-26 Use of ibudilast for treating drug and behavioral addictions

Publications (1)

Publication Number Publication Date
PL1928438T3 true PL1928438T3 (pl) 2013-08-30

Family

ID=37806904

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06815512T PL1928438T3 (pl) 2005-09-26 2006-09-26 Zastosowanie ibudilastu do leczenia uzależnień od środków odurzających

Country Status (12)

Country Link
US (1) US7915285B2 (pl)
EP (1) EP1928438B1 (pl)
JP (1) JP5411504B2 (pl)
AU (1) AU2006294758A1 (pl)
BR (1) BRPI0616344A2 (pl)
CA (1) CA2623072A1 (pl)
DK (1) DK1928438T3 (pl)
ES (1) ES2412858T3 (pl)
PL (1) PL1928438T3 (pl)
PT (1) PT1928438E (pl)
RU (1) RU2008116720A (pl)
WO (1) WO2007038551A2 (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0616344A2 (pt) 2005-09-26 2011-06-14 Avigen Inc mÉtodo para o tratamento de dependÊncia quÍmica e comportamental
US20110275664A1 (en) * 2005-09-26 2011-11-10 The Regents Of The University Of Colorado,A Body Corporate Method for treating drug and behavioral addictions
US20070281924A1 (en) * 2006-05-31 2007-12-06 Gaeta Federico C MIF inhibitors for treating neuropathic pain and associated syndromes
CA2653345A1 (en) * 2006-05-31 2007-12-13 Avigen, Inc. Ibudilast for inhibiting macrophage migration inhibitory factor (mif) activity
EP2073813A2 (en) * 2006-10-10 2009-07-01 The University of Chicago Composition s comprising a benzodiazepine, an alcohol aversive agent and an abuse aversive agent
CA2669463A1 (en) * 2006-11-09 2008-05-15 Avigen, Inc. Method for treating delirium
JP2010513569A (ja) * 2006-12-19 2010-04-30 ユニバーシティ オブ バージニア パテント ファウンデーション アルコール摂取に対するトピラメートおよびオンダンセトロンの併用効果
US20080181876A1 (en) * 2007-01-30 2008-07-31 Johnson Kirk W Methods for treating acute and subchronic pain
CA2677205A1 (en) * 2007-01-31 2008-08-07 University Of Virginia Patent Foundation Topiramate plus naltrexone for the treatment of addictive disorders
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
WO2008137012A1 (en) * 2007-05-03 2008-11-13 Avigen, Inc. Use of a glial attenuator to prevent amplified pain responses caused by glial priming
US20090028816A1 (en) * 2007-07-27 2009-01-29 Lance Sultzbaugh Treatment of depression, psychosis, and anxiety
WO2009029308A1 (en) * 2007-08-27 2009-03-05 University Of Virginia Patent Foundation Medication combinations for the treatment of alcoholism and drug addiction
MX2010009509A (es) 2008-02-28 2010-11-30 Univ Virginia Gen transportador de serotonina y tratamiento de alcoholismo.
US9226918B2 (en) * 2008-12-04 2016-01-05 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating or preventing narcotic withdrawal symptoms
WO2011087755A2 (en) * 2009-12-22 2011-07-21 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
US20110218215A1 (en) * 2010-03-04 2011-09-08 Holly Benjamin D Compositions and Methods for Treating Social Anxiety
EA024450B1 (ru) 2010-07-02 2016-09-30 Юниверсити Оф Вирджиния Пэтент Фаундейшн Молекулярно-генетический подход к лечению и диагностике алкогольной и наркотической зависимости
NZ628054A (en) 2010-11-08 2016-03-31 Omeros Corp Treatment of addiction and impulse-control disorders using pde7 inhibitors
AU2013201989B2 (en) * 2010-11-08 2016-01-07 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
CA2845039A1 (en) * 2011-08-18 2013-02-21 Shire Ag Combinations of a 5-ht4 receptor agonist and a pde4 inhibitor for use in therapy
EP2751137A4 (en) 2011-09-09 2015-06-03 Univ Virginia Patent Found MOLECULAR GENETIC APPROACH FOR THE TREATMENT AND DIAGNOSIS OF ALCOHOL AND DRUG INDEPENDENCE
US9610285B2 (en) 2011-11-16 2017-04-04 University Of Florida Research Foundation, Incorporated Compositions for controlling food intake and uses therefor
DK2846805T3 (en) * 2012-05-07 2019-03-18 Omeros Corp TREATMENT OF DEPENDENCE AND IMPULSE CONTROL DISORDERS USING PDE7 INHIBITORS
SI2846805T1 (sl) * 2012-05-07 2019-04-30 Omeros Corporation Zdravljenje zasvojenosti in motenj v obvladovanju impulzov z uporabo inhibitorjev PDE7
WO2015023871A1 (en) * 2013-08-15 2015-02-19 Medicinova, Inc. Treatment of alcoholism using ibudilast
US9192570B2 (en) 2013-12-20 2015-11-24 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US10188645B2 (en) * 2015-08-26 2019-01-29 Ian Cain Smith Methods and compositions for ameliorating symptoms of termination of opioid pain therapy
WO2017196857A1 (en) * 2016-05-10 2017-11-16 Medicinova, Inc. Treatment of alcoholism and depression and/or dysphoric mood using ibudilast
US20190201494A1 (en) * 2016-09-13 2019-07-04 Stc Unm Compositions and methods for treating nicotine withdrawal
WO2019055942A1 (en) * 2017-09-18 2019-03-21 SEN-JAM Pharmaceutical LLC METHODS AND COMPOSITIONS FOR INHIBITING OPIOID TOLERANCE
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496836A (en) * 1994-05-05 1996-03-05 Mount Sinai School Of Medicine Of The City University Of New York Use of famotidine and related compounds in the treatment of movement disorders
JP3601898B2 (ja) * 1996-02-14 2004-12-15 俊隆 鍋島 薬物依存形成抑制剤
WO1999063929A2 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
US6057368A (en) * 1998-08-05 2000-05-02 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
FR2797402B1 (fr) * 1999-07-15 2004-03-12 Biomerieux Stelhys Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
US6953774B2 (en) * 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
MY140679A (en) 2001-05-24 2010-01-15 Avanir Pharmaceuticals Inhibitors of macrohage migration inhibitory factor and methods for identifying the same
NZ537301A (en) 2002-06-07 2006-06-30 Cortical Pty Ltd Therapeutic molecules and methods-1
CN1675154A (zh) 2002-06-07 2005-09-28 科蒂科股份有限公司 抑制巨噬细胞移动抑制因子(mif)的细胞因子或生物活性的萘衍生物
US20060106054A1 (en) * 2002-12-03 2006-05-18 Michiaki Nagasawa Phosphodiesterase 10a inhibitors
US7125997B2 (en) 2002-12-20 2006-10-24 Irm Llc Differential tumor cytotoxicity compounds and compositions
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
WO2005058304A1 (en) 2003-12-17 2005-06-30 Cortical Pty Ltd Implantable device containing inhibitor of macrophage migration inhibitory factor
GB0423405D0 (en) 2004-10-21 2004-11-24 Novartis Ag Organic compounds
MX2007006777A (es) 2004-12-06 2007-08-06 Avigen Inc Ibudilast para tratar dolor neuropatico y sindromes asociados.
GB0507695D0 (en) 2005-04-15 2005-05-25 Novartis Ag Organic compounds
BRPI0616344A2 (pt) 2005-09-26 2011-06-14 Avigen Inc mÉtodo para o tratamento de dependÊncia quÍmica e comportamental
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2653345A1 (en) 2006-05-31 2007-12-13 Avigen, Inc. Ibudilast for inhibiting macrophage migration inhibitory factor (mif) activity
CA2669463A1 (en) 2006-11-09 2008-05-15 Avigen, Inc. Method for treating delirium
US20080181876A1 (en) 2007-01-30 2008-07-31 Johnson Kirk W Methods for treating acute and subchronic pain

Also Published As

Publication number Publication date
EP1928438A2 (en) 2008-06-11
AU2006294758A1 (en) 2007-04-05
RU2008116720A (ru) 2009-11-10
JP2009509975A (ja) 2009-03-12
CA2623072A1 (en) 2007-04-05
EP1928438B1 (en) 2013-03-20
JP5411504B2 (ja) 2014-02-12
PT1928438E (pt) 2013-04-03
US7915285B2 (en) 2011-03-29
WO2007038551A2 (en) 2007-04-05
WO2007038551A3 (en) 2007-06-28
US20070072899A1 (en) 2007-03-29
ES2412858T3 (es) 2013-07-12
BRPI0616344A2 (pt) 2011-06-14
HK1120737A1 (en) 2009-04-09
DK1928438T3 (da) 2013-04-22

Similar Documents

Publication Publication Date Title
PL1928438T3 (pl) Zastosowanie ibudilastu do leczenia uzależnień od środków odurzających
GB0602178D0 (en) Therapeutic treatment
IL198663A0 (en) Tissue treatment methods
ZA200805716B (en) Use of nitrooxyderivative of drug for the treatment of muscular dystrophies
PL2034920T3 (pl) Urządzenie do laserowych zabiegów dermatologicznych
GB0606604D0 (en) Treatment apparatus
BRPI0914294A2 (pt) aparelho de tratamento de cápsulas
EP2078536A4 (en) MEDICAL DEVICE
IL193747A0 (en) New therapeutic combinations for the treatment of depression
NO2016023I1 (no) Glycerol fenylbutyrat
AP2008004593A0 (en) Antivral drugs for treatment of arenavirus infection
ITRE20060026A1 (it) Apparecchio per trattamenti medicinali
ITRE20060127A1 (it) Apparecchio per trattamenti medicali
HRP20181877T1 (hr) Postupci za liječenje lijekovima koji uklanjaju amonijak
IL187715A0 (en) Use of phenylsemicarbazones for seed treatment
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
GB2452204B (en) Head worn medical treatment apparatus
GB0608655D0 (en) Therapeutic Treatment
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
EP1842498A4 (en) TREATMENT DEVICE FOR AN ENDOSCOPE
GB0610909D0 (en) Therapeutic treatment
ZA200904478B (en) Novel therapeutic use for treating leukaemia
SI1928438T1 (sl) Uporaba ibudilasta za zdravljenje zasvojenosti z drogami
ZA200800393B (en) Use of phenylsemicarbazones for seed treatment
GB0625112D0 (en) Apparatus for skin treatment